Post-earnings recap
Reported
Thu, May 5, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioCryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 9% decline in stock price. The absence of revenue figures and guidance adds to investor uncertainty. The management's defensive tone suggests that the company may face challenges ahead, impacting investor confidence.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -34.20% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance and the lack of guidance indicates uncertainty. They highlighted ongoing efforts to improve operations.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability in the near term.